COL1A2 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: COL1A2 Antibody - Azide and BSA Free [NBP2-92790] -

Immunocytochemistry/ Immunofluorescence: COL1A2 Antibody - Azide and BSA Free [NBP2-92790] - Immunofluorescence analysis of NIH/3T3 cells using COL1A2 Rabbit pAb at dilution of 1:25. Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.

Western Blot: COL1A2 Antibody - BSA Free [NBP2-92790] -

IAV infection induced dysregulation of profibrotic progression exacerbated in Rev-erb alpha Het mice.WT and Rev-erb alpha Het mice (equal number of male and female) infected (103 PFU/mouse) with IAV for 15 days, and lungs were separated for RNA/protein isolation, or fixed with 10% formalin for FFPE sections. a The protein abundance of COL1A2, VIM and activated LOX were measured by western blot. Representative blot images were shown. Different targets were run on the same membrane: COL1A2, VIM and activated LOX were probed in the same membrane and beta -ACTIN was used as an endogenous control (n = 5–6 mice per group). b The localizations of COL1A1 and LOX were determined by immunohistochemical staining, and red arrows were used to indicate the regions of interest. The positive staining area was calculated via ImageJ (n = 4–6 mice per group). c RNA isolated from lung homogenates was used to measure the gene expression (COL1A1, FN1, TJP1 and TGFB1) via qRT-PCR, and GAPDH was used as an endogenous gene for normalization (n = 5–6 mice per group). Data are shown as mean +/- SEM, one-way ANOVA followed Šidak’s multiple comparisons test was used in a–c. Bar size: 50 um in b. (n = 4–6; *p < 0.05, **p < 0.01, ***p < 0.001 between groups; #p < 0.05, ##p < 0.01 compared with IAV infected WT group). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36894533), licensed under a CC-BY license. Not internally tested by Novus Biologicals.